Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 5 de 5
Filtre
1.
Indian J Exp Biol ; 2023 Jan; 61(1): 14-24
Article | IMSEAR | ID: sea-222582

Résumé

The immune response, orchestrated by helper (Th1, Th2, and Th17) and regulatory (Treg) T cells, is modulated by stress and Vitamin D (Vit-D). Although the immunomodulatory functions of both are known, their specific roles on Th cells have not been fully clarified, yet. On this background, we aimed to investigate the effect of acute or subchronic stress on the distribution of peripheral T lymphocytes, as well as the immunomodulatory role of Vit-D. Young adult male, Swiss-albino mice (30–40g) were allocated to the control, acute stress (AS), subchronic stress (ChS), control+Vit-D, AS+Vit-D, and ChS+Vit-D groups (n=11/group). The combined cold (2-h at 4°C)-immobilization (2-h in a restrainer) stress protocol was employed as one day in AS groups and five consecutive days in ChS groups. Vit-D (2?g/kg ip) was applied every other day, until the end of the protocol. Serum cortisol, Vit-D and cytokine levels (IL-4, IFN-?, and IL-17A) were measured, and lymphocytes from blood samples were subtyped by flow-cytometry. Stress exposure caused differential Th and Treg responses, acute stress shifting the response to Th1, and subchronic stress shifting the response to Th2. Th17 and Treg cells were lower in subchronic stress exposed mice. These changes became comparable to control values in Vit-D treated groups. The T cell response, crucial for immune system function, differs on the basis of stress exposure as such the Vit-D treatment. The tolerogenic profile created by Vit-D should be considered for management of stress-related diseases. Our results may help to provide a better understanding of disease pathogenesis.

2.
Braz. J. Pharm. Sci. (Online) ; 58: e191120, 2022. tab, graf
Article Dans Anglais | LILACS | ID: biblio-1394048

Résumé

Abstract The aim of the current study was to assess the physicochemical characteristics and wound healing activity of chitosan-polyvinyl alcohol (PVA) crosslinked hydrogel containing recombinant human epidermal growth factor (rh-EGF) or recombinant mouse epidermal growth factor (rm-EGF). The hydrogels were prepared and analyses were made of the morphological properties, viscosity, water absorption capacity, mechanical and bio-adhesive properties. The viscosity of the formulations varied between 14.400 - 48.500 cPs, with the greatest viscosity values determined in K2 formulation. F2 formulation showed the highest water absorption capacity. According to the studies of the mechanical properties, H2 formulation (0.153±0.018 N.mm) showed the greatest adhesiveness and E2 (0.245±0.001 mj/cm2) formulation, the highest bio-adhesion values. Hydrogels were cytocompatible considering in vitro cell viability values of over 76% on human keratinocyte cells (HaCaT, CVCL-0038) and of over 84% on human fibroblast cells (NIH 3T3, CRL-1658) used as a model cell line. According to the BrdU cell proliferation results, B1 (197.82±2.48%) formulation showed the greatest NIH 3T3 and C1 (167.43±5.89%) formulation exhibited the highest HaCaT cell proliferation ability. In addition, the scratch closure assay was performed to assess the wound healing efficiency of formulation and the results obtained in the study showed that F2 formulation including PEGylated rh-EGF had a highly effective role.


Sujets)
Cicatrisation de plaie , Hydrogels/analyse , Chitosane/synthèse chimique , Facteur de croissance épidermique , Poly(alcool vinylique)/pharmacologie , Plaies et blessures/classification , Techniques in vitro/méthodes , Techniques de culture cellulaire/méthodes , Prolifération cellulaire/génétique , Absorption
3.
Indian J Pediatr ; 2010 June; 77(6): 681-683
Article Dans Anglais | IMSEAR | ID: sea-142606

Résumé

Four children with vincristine (VCR)-induced neuropathy are being reported. All cases were followed with the diagnosis of acute lymphoblastic leukemia. Two were boys aged between 2 and 13 year. Electromyographic examination consisted of sensoriomotor polyneuropathy with axonal involvement in three patients. In another patient, it consisted of motor axonal polyneuropathy. In all patients, pyridoxine and pyridostigmine were successfully used in the treatment of VCR-induced neuropathy. They recovered completely with this drug combination. Recovering period of symptoms was between 1-2 week.


Sujets)
Adolescent , Antinéoplasiques d'origine végétale/administration et posologie , Antinéoplasiques d'origine végétale/effets indésirables , Enfant , Enfant d'âge préscolaire , Anticholinestérasiques/usage thérapeutique , Association de médicaments , Femelle , Humains , Mâle , Polyneuropathies/induit chimiquement , Polyneuropathies/diagnostic , Polyneuropathies/traitement médicamenteux , Leucémie-lymphome lymphoblastique à précurseurs B et T/diagnostic , Leucémie-lymphome lymphoblastique à précurseurs B et T/traitement médicamenteux , Bromure de pyridostigmine/usage thérapeutique , Pyridoxine/usage thérapeutique , Résultat thérapeutique , Vincristine/administration et posologie , Vincristine/effets indésirables , Complexe vitaminique B/usage thérapeutique
4.
Indian J Pediatr ; 2009 Nov; 76(11): 1141-1144
Article Dans Anglais | IMSEAR | ID: sea-142425

Résumé

Objective. To evaluate the rituximab treatment in children with chronic immune thrombocytopenic purpura Methods. This study included ten children with chronic immune thrombocytopenic purpura, which were nonresponsive to Steroid (S), IVIG and anti-D treatments. Rituximab was given with a dosage of 375 mg/m2 weekly for 4-6 weeks. Initial platelet count was less than 30x109/L and responses were assessed in follow-up. The patients’ groups were categorized as complete remission (CR);a platelet count ≥150x109/L,partial remission (PR);a platelet count ranging from 50x109/L to 150x109/L, minimal remission (MR); a platelet count ranging from 30x109/L to 50x109/L and no response (NR); a platelet count less than 30x109/L. Results. Of our patients, four female and six male, their ages ranged from 39 mth to 13 yr and the mean age was 83.4±44.58 mo. None of the patients was splenectomized. The follow-up period after rituximab treatment ranged between 12 to 42 mo and the mean follow-up period was 25.10±13.03 months. While on this treatment, we had a CR in two patients, a PR in one, a MR in three, but no response in four. The patients in CR/PR are still being followed as in remission and they have 40 mo of mean follow-up period. The three patients in MR had a decrease in values of platelets earliest in one mo and the latest in four mo. Adverse effects of rituximab, such as itching and scraps that were not clinically significant were observed in three patients during rituximab infusion. There were no increase in infections after rituximab in any patient. Conclusion. CR was found in 20% of our patients, PR in 10% and MR in 30% with rituximab. On this treatment, while some series had good outcomes with this treatment (72%-100%, remission ratios), but many series, such as ours, had a poor response rate contrast to many reported case series in the literature. This condition may be associated with the age of our most patients who were young at the time of commenced rituximab. However, we believe that more studies are required to elucidate the reasons for different results in different case series reported in literature.


Sujets)
Adolescent , Anticorps monoclonaux/usage thérapeutique , Anticorps monoclonaux d'origine murine , Autoanticorps/immunologie , Enfant , Enfant d'âge préscolaire , Maladie chronique , Femelle , Études de suivi , Humains , Facteurs immunologiques/usage thérapeutique , Mâle , Purpura thrombopénique idiopathique/traitement médicamenteux , Purpura thrombopénique idiopathique/immunologie
5.
Indian J Pediatr ; 2007 Aug; 74(8): 790-2
Article Dans Anglais | IMSEAR | ID: sea-82986

Résumé

We present two patients with brucellosis concomitant with acute leukemia. Co-existence of acute leukemia with brucellosis which may have similar symptoms, have not been reported earlier. The first case presented with generalized arthralgia, fever, paleness and pancytopenia. The second patient had mild leucopenia and thrombocytopenia. She presented with fever. We carried out the chemotherapy for both ALL and brucellosis simultaneously. While the first patient's fever disappeared within 3 days, the second patient's fever had continued on subfebril level for five days and then disappeared. We achieved the remission in both patients and no reactivation was observed during the follow-up period.


Sujets)
Antibactériens/usage thérapeutique , Antinéoplasiques/usage thérapeutique , Brucellose/complications , Enfant d'âge préscolaire , Diagnostic différentiel , Femelle , Fièvre , Humains , Mâle , Pancytopénie/étiologie , Leucémie-lymphome lymphoblastique à précurseurs B et T/complications
SÉLECTION CITATIONS
Détails de la recherche